Business Context and Reporting Period
This Form 8-K is a current report filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on October 15, 2019. The filing addresses significant changes in executive leadership and board composition effective immediately on the report date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departures: Stephen Hoffman resigned as Chief Executive Officer, Principal Executive Officer, and Director. Michael Rogers resigned as Chief Financial and Business Officer, Principal Financial Officer, and Principal Accounting Officer.
- Appointments: Joseph Gardner (President and Founder) was appointed as Principal Executive Officer. Regina Marek (Vice President of Finance) was appointed as Principal Financial Officer and Principal Accounting Officer.
Management Commentary, Risks, and Unusual Items
Compensatory Arrangements for New Appointees:
- Joseph Gardner: No change is anticipated in his compensatory arrangement. No family relationships or undisclosed understandings regarding his selection were reported.
- Regina Marek:
- Base Salary: $240,000 annually.
- Bonus: Target annual performance bonus of 30% of base salary.
- Equity: Retention stock option for 153,300 shares (vesting 50% on June 30, 2020, and 50% on June 30, 2021). Previous option grant of 80,000 shares from August 2018 remains in effect.
- Cash Retention: $120,000 payment expected at the end of the second quarter of fiscal year 2020.
- Severance: If terminated without Cause, she is entitled to six months of base salary plus one week per year of service, plus six months of health benefits.
Risks and Contingencies: The Company has entered into a standard indemnification agreement with Ms. Marek, which may require the Company to indemnify her for expenses, judgments, fines, and settlement amounts arising from her service as an officer. She is also bound by non-competition and non-solicitation provisions for one year post-employment.
Investor Verification Checklist
- Verify the immediate departure of the CEO and CFO and the potential impact on ongoing clinical trials or business strategy.
- Confirm the vesting schedules and exercise prices for the stock options granted to Regina Marek.
- Review the Company's cash position to assess the impact of the $120,000 retention payment and potential severance obligations.
- Check for any subsequent filings regarding the appointment of a new Chief Executive Officer, as Joseph Gardner was appointed only as Principal Executive Officer.